Myriad Genetics Inc (MYGN)

Currency in USD
5.19
+0.28(+5.70%)
Closed·
5.09-0.10(-1.93%)
·

Myriad Genetics (MYGN) Earnings Dates & Reports

Latest Release
Feb 23, 2026
EPS / Forecast
0.04 / -0.02
Revenue / Forecast
209.8M / 207.17M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/-0.068--/202.39M----Free Sign Up
12/20250.040/-0.020209.80M/207.17M+300%+1.27%Free Sign Up
09/20250.000/-0.010205.70M/204.97M+100%+0.36%Free Sign Up
06/20250.050/-0.010213.10M/201.91M+600%+5.54%Free Sign Up
03/20250.000/-0.060195.90M/200.90M+100%-2.49%Free Sign Up
12/20240.030/0.030211.00M/213.31M0%-1.08%Free Sign Up
09/20240.060/0.020213.30M/210.76M+200%+1.21%Free Sign Up
06/20240.050/-0.012211.50M/206.44M+527.35%+2.45%Free Sign Up
03/2024-0.010/-0.010202.20M/202.20M0%0%Free Sign Up
12/20230.040/0.010196.60M/194.80M+300%+0.92%Free Sign Up

All numbers in USD

Myriad Genetics Inc Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of $0.04 beat forecast by 300%; revenue of $209.8M exceeded estimates by 1.27%, driving 2.33% stock gain to $4.33
  • Delivered 382,000 tests (up 2% YoY); achieved 4% underlying revenue growth despite UnitedHealthcare policy headwinds on GeneSight product
  • Adjusted gross margin of 70% (down 190 bps YoY); adjusted EBITDA reached $14.3M with $225M in available capital for strategic initiatives
  • FY 2026 revenue guidance set at $867.18M; planning Q2 2026 launches of AI-enhanced prostate cancer tests and MyRisk oncology disease panels
  • Management focuses on payer diversification to offset policy changes; analysts predict profitability in 2026 with price targets ranging $4-$18
Last Updated: 02/23/2026, 05:50 PM
Read Full Transcript
Myriad Genetics investor slides for Q4/2025
Myriad Genetics Q4 2025 slides
Last Update: Feb 23, 2026
See full investor slides

FAQ

What Is Myriad Genetics's Earnings Per Share (TTM)?

The Myriad Genetics EPS (TTM) is -3.95.

When Is The Next Myriad Genetics Earnings Date?

Myriad Genetics will release its next earnings report on Apr 30, 2026.

What Is Myriad Genetics’s Revenue Forecasts For Upcoming Quarters?

Myriad Genetics’s revenue forecast is 202.39M.

How Did Myriad Genetics React to the Company's Latest Earnings Report?

Myriad Genetics reported a +300% EPS surprise and a +1.27% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 3.26%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.